Skip to main content
Premium Trial:

Request an Annual Quote

Mitsubishi-Tokyo Makes Equity Investment in Quark Biotech

NEW YORK, Sept. 11 – Quark Biotech said Tuesday that Mitsubishi-Tokyo Pharmaceuticals of Japan has made an equity investment in the company of an undisclosed amount.

Quark and Mitsubishi-Tokyo, a wholly owned subsidiary of Mitsubishi Chemical Corporation, are currently collaborating to develop drug targets for neurodegenerative diseases as well as other disease areas.

"QBI's team, along with its applied genomics technology, will greatly accelerate the drug discovery and development activities of our company," Akihiro Tobe, president of research and development of Mitsubishi-Tokyo said in a statement. 

In addition to the equity investment, Mitsubishi-Tokyo will continue to fund research at QBI and collaborate with QBI scientists. QBI will receive royalties on sales of the products developed from this collaboration, as well as milestone payments. 

Quark Biotech is a functional genomics company based in Cleveland that uses knockout mice technology to validate its findings.

Other investors in Quark include Japan’s  Fugisawa Pharmaceutical and Taisho Pharmaceutical as well as Larry Ellison, CEO of Oracle.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.